Table 1: Characteristics of included studies.

Study
ID
Subjects
(T/C)
Age (years)
(T/C)
Diagnostic
criteria
InterventionMain outcome measuresCourse of
Treatment
Language of
Publication
TC

Zhang
2008
57/49T:51±9
C: 51±10
1999
WHO
berberine+
Metformin
placebo+
Metformin
HbA1c
FBG
2hPG
12 weeksEnglish

Tong
2013
292/107T:54.4±7.7
C:54.5±7.6
1999
WHO
TM81+
Metformin
placebo+
Metformin
HbA1c
FBG
2hPG
12 weeksEnglish

Ji2013a164/160T:54±9
C:54±8
1999
WHO
Xiaoke pills+
Glibenclamide
GlibenclamideHbA1c
FBG,
2hPG
48 weeksEnglish

Ji2013b153/150T:54±8
C:55±9
1999
WHO
Xiaoke pills+
Glibenclamide+
Metformin
Glibenclamide +
Metformin
HbA1c
FBG,
2hPG
48 weeksEnglish

Lian
2015
92/94T:55.18±9.13 C:55.81±9.931999
WHO
Jinlida
+
Metformin
Placebo
+
Metformin
HbA1c
FBG,
2hPG
12 weeksEnglish

Hu
2016
59/53T:56.3±11.1 C:54.9±10.31999
WHO
Jian yu tang
Kang
+
Metformin
Placebo
+
Metformin
HbA1c
FBG,
2hPG
26 weeksEnglish

Xu
2014
52/41
T:55.06±7.49
C: 50.7±9.40
1999
WHO
Ge Gen Qin Lian+
Metformin
placebo+
Metformin
HbA1c
FBG,
2hPG
12 weeksEnglish

Wangsh
2014
89/89T:56.27±9.8
C:55. 78±9.17
1999
WHO
Tang ke+
Metformin
Placebo+
Metformin
HbA1c
FBG,
2hPG
12 weeksChinese

Tong
2009
67/69T:52.93±6.58 C:52.4±8.61
1999
WHO
TangMinling pills+
Metformin
Placebo+
Metformin
HbA1c
FBG,
2hPG
12 weeksChinese

Lian
2011
40/39T:53.3±6.98
C:56.4±9.00
1999
WHO
Tian Qi Jiang Tang
+
Metformin
Placebo
+
Metformin
HbA1c
FBG,
2hPG
12 weeksChinese

Wang
2014
49/44T:59.00±6.5
C:63.00±5.6
1999
WHO
Liuwei Dihuang
Combined
With
Ginkgo Leaf+
Metformin
placebo+
Metformin
HbA1c
FBG,
2hPG
96 weeksChinese